Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2118 Monotherapy and Combo with Pembrolizumab in Advanced Tumors
NCT03249792Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of MK-2118 in solid tumor and lymphoma (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience One or More Dose-limiting Toxicities, Number of Participants Who Experience One or More Adverse Events and 1 more. Started Sep 2017; status: terminated.
02
Drugs
MK-2118
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03249792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249792.